Melanoma

Roberts DL, Anstey AV, Barlow RJ, Cox NH, Newton Bishop JA, Corrie PG, Evans J, Gore ME, Hall PN, Kirkham N, Anonymous00200, Anonymous00201. · Singleton Hospital, Swansea SA2 8QA, UK. · Br J Dermatol. · Pubmed #11841361 No free full text.

Abstract: These guidelines for management of cutaneous melanoma present evidence-based guidance for treatment, with identification of the strength of evidence available at the time of preparation of the guidelines, and a brief overview of epidemiological aspects, diagnosis and investigation. To reflect the collaborative process for the U.K., they are subject to dual publication in the British Journal of Dermatology and the British Journal of Plastic Surgery.

Sober AJ, Chuang TY, Duvic M, Farmer ER, Grichnik JM, Halpern AC, Ho V, Holloway V, Hood AF, Johnson TM, Lowery BJ, Anonymous00178. · No affiliation provided · J Am Acad Dermatol. · Pubmed #11568750 No free full text.

This publication has no abstract.

Dummer R, Bösch U, Panizzon R, Bloch PH, Burg G, Anonymous00035. · Department of Dermatology, University Hospital of Zürich, Switzerland. · Dermatology. · Pubmed #11549807 No free full text.

Abstract: Melanoma is the most common lethal cutaneous neoplasm. There is major controversy over the best management of this malignancy. In order to harmonize treatment and follow-up of melanoma patients, guidelines for the management of melanoma in Switzerland have been inaugurated. They have been approved by all Swiss medical societies involved in the care of melanoma patients.

Négrier S, Fervers B, Bailly C, Beckendorf V, Cupissol D, Doré JF, Dorval T, Garbay JR, Vilmer C, Anonymous00212. · Centre Léon Bérard, Lyon, France. · Br J Cancer. · Pubmed #11355977 links to  free full text

This publication has no abstract.

Calonje E. · Department of Dermatopathology, St John's Institute of Dermatology, St Thomas's Hospital, London, UK. · J Clin Pathol. · Pubmed #11002760 links to  free full text

Abstract: The incidence of malignant melanoma has increased steadily over the past 30 years and this type of malignancy is the leading cause of death from cutaneous malignant disease. Cutaneous malignancies, including melanoma, can be detected at a very early stage and a cure is possible with prompt detection and treatment. In recent years, and mainly because of increased awareness of the early detection of melanoma, histopathologists have been exposed more and more to melanocytic lesions. Therefore, it is essential that histopathologists are able to provide a report to the clinician that conveys relevant information in a concise and precise manner. This paper provides a set of guidelines aimed at helping histopathologists with the gross and microscopic description and diagnosis of malignant melanoma.

Négrier S, Fervers B, Bailly C, Beckendorf V, Cupissol D, Doré JF, Dorval T, Garbay JR, Vilmer C. · No affiliation provided · Presse Med. · Pubmed #10923143 No free full text.

This publication has no abstract.

Anonymous58757. · No affiliation provided · Clin Oncol (R Coll Radiol). · Pubmed #10853743 No free full text.

Abstract: Chordomas of the base of the skull are rare. They are locally infiltrative and frequently arise close to radiosensitive structures, which limits the ability to deliver a high dose of radiotherapy. Complete surgical excision is not usually possible. Conventional postoperative radiotherapy can result in approximately 50% 5-year survival and effective palliation, but long-term local control and cure are rare. The well-defined Bragg peak of protons allows planning with a sharp cut-off outside the target volume. This permits a higher dose of radiotherapy to be delivered to the tumour while avoiding excessive irradiation to radiosensitive structures. Outcome after proton irradiation is superior to that reported for conventional photon irradiation. Radiotherapy schedules involving a mixed schedule of protons and photons have achieved an approximately 60% local control rate at 5 years. Some of this improvement may have resulted from better surgical techniques. Proton irradiation is also effective for base of skull chondrosarcomas. Protons of sufficient energy to treat base of skull tumours are not available in the UK. Patients have been referred to the proton facilities at the Harvard cyclotron, and at Orsay, France. They will continue to require referral abroad for proton therapy for base of skull tumours. Proton therapy has become standard treatment for ocular melanoma and this is available at the Douglas cyclotron at Clatterbridge Hospital. Proton therapy has the potential for improved dose distribution compared with conformal photon radiotherapy. This may be exploited effectively to irradiate target volumes close to radiosensitive structures such as the spinal cord. There is a need for further clinical research to evaluate proton therapy for tumours such as spinal and paraspinal sarcomas, and paediatric brain tumours.

Anonymous58677. · No affiliation provided · Pathologica. · Pubmed #10843001 No free full text.

This publication has no abstract.

Négrier S, Fervers B, Bailly C, Beckendorf V, Cupissol D, Doré JF, Dorval T, Garbay JR, Vilmer C. · FNCLCC, Standards, Options, Recommandations, 101, rue de Tolbiac, 75654 Paris Cedex 13. · Bull Cancer. · Pubmed #10705288 links to  free full text

Abstract: CONTEXT: The "Standards, Options and Recommendations" (SOR) project, started in 1993, is a collaboration between the Federation of the French Cancer Centres (FNCLCC), the 20 French Cancer Centres and specialists from French Public Universities, General Hospitals and Private Clinics. The main objective is the development of clinical practice guidelines to improve the quality of health care and outcome for cancer patients. The methodology is based on literature systematic review and critical appraisal by a multidisciplinary group of experts, with feedback from specialists in cancer care delivery. OBJECTIVES: To develop clinical practice guidelines according to the definitions of Standards, Options and Recommendations for the management of patients with cutaneous melanoma. METHODS: Data have been identified by literature search using Medline - until December 1998 - and the personal reference lists of the expert group. Once the guidelines were defined, the document was submitted for review to national and international independent reviewers and to the medical committees of the 20 French Cancer Centres. RESULTS: The main recommendations for the management of cutaneous melanoma (CM) are: 1) The primary prevention of melanoma is based on a reduction in exposure to ultraviolet rays (solar or artificial). 2) The diagnosis of CM requires the surgical removal and histological examination of the lesion (standard). 3) The pathological report must include the diagnosis of primary malignant melanoma, the maximum thickness of the tumour in millimeters (Breslow), the clearance of surgical margins, the level of invasion (Clark), the presence and extension of regression and the presence of any ulceration (standard). 4) The standard treatment of a primary melanoma without lymph node involvement is based on surgery that must ensure adequate margins depending on the thickness of the tumour (standard, level of evidence B). 5) After surgery of a stage I melanoma, there is no indication for additional treatment outside a prospective therapeutic study (standard, level of evidence B, French Consensus Conference). 6) For a local recurrence without node involvement, in the absence of other metastases, surgical excision is the standard treatment. 7) In the case of metastatic regional lymph nodes, a complete regional lymphadenectomy is required. There is no indication for additional treatment outside a prospective therapeutic study (standard, level of evidence B). The inclusion of these patients in controlled studies of immunotherapy is recommended. 8) There is no standard therapeutic strategy for metastatic melanoma. Conventional palliative treatment is chemotherapy with dacarbazine (level of evidence B). 9) Follow-up is based on physical examination (standard). Patient information must encourage self-surveillance. Clinical surveillance and self-detection are indicated in all cases throughout life (standard).

Wilkinson EJ. · University of Florida, Gainesville, Florida, USA. · Arch Pathol Lab Med. · Pubmed #10629132 No free full text.

This publication has no abstract.

Anonymous55020. · No affiliation provided · Pediatrics. · Pubmed #10429020 No free full text.

This publication has no abstract.

Lim HW, Cooper K. · American Academy of Dermatology, Inc., Schaumburg, IL 60168-4014, USA. · J Am Acad Dermatol. · Pubmed #10411417 No free full text.

Abstract: It is well recognized that exposure to solar radiation is a major risk factor for the development of skin cancer, photoaged skin, and immune system alterations. However, major questions remain regarding the specific wavelengths and type of exposure that incur risk. The purpose of this article is to critically examine, on the basis of current knowledge, the impact of stratospheric ozone depletions, tanning bed skin cancer risk, the safety of sunscreens as an important element of our solar protection strategies, the wavelengths of solar radiation responsible for melanoma, and the incidence of melanoma. Recommendations are made on prevention strategies and public health messages.

Dinulos J. · No affiliation provided · Curr Opin Pediatr. · Pubmed #19617832 No free full text.

This publication has no abstract.

Li B, Xu XL. · No affiliation provided · Zhonghua Yan Ke Za Zhi. · Pubmed #19575957 No free full text.

Abstract: Uveal melanoma (UM) is the most common intraocular malignant tumor in the adults. So far, known treatments have not been able to effectively improve the prognosis of the patients' life and the survival rate. Based on the above issues, it is imperative to think of what can we do for uveal melanoma. This paper reviews using local preservative therapy in combined treatment of UM, how to predict and evaluate the risk of metastasis, how to detect early metastasis, and whether or not systemic therapy to UM patients is necessary. We hope that through etiological study and through the evaluation of the effects of combined treatment of UM by large sample prospective control studies, we can find an effective therapy which can save the patients' eye and useful vision while simultaneously improving the prognosis, and ultimately, improving clinical diagnosis and treatment of UM in China.

Zager JS, Weber JS. · No affiliation provided · Cancer Control. · Pubmed #19556959 links to  free full text

This publication has no abstract.

West DW, Clarke CA. · No affiliation provided · Cancer Epidemiol Biomarkers Prev. · Pubmed #19505898 No free full text.

This publication has no abstract.

Goding C. · No affiliation provided · Pigment Cell Melanoma Res. · Pubmed #19490498 No free full text.

This publication has no abstract.

Arbiser JL, Bonner MY. · No affiliation provided · Arch Dermatol. · Pubmed #19451506 No free full text.

This publication has no abstract.

Daniels AB, Abramson DH. · No affiliation provided · Arch Ophthalmol. · Pubmed #19433723 No free full text.

This publication has no abstract.

Glaspy J, Ribas A, Chmielowski B. · No affiliation provided · J Clin Oncol. · Pubmed #19433677 No free full text.

This publication has no abstract.

Robinson JK, Mallett KA, Turrisi R, Stapleton J. · Northwestern University Feinberg School of Medicine, 132 E Delaware Pl, No. 5806, Chicago, IL 60611, USA. · Arch Dermatol. · Pubmed #19380671 No free full text.

This publication has no abstract.

Kirkwood JM, Tarhini AA. · No affiliation provided · J Clin Oncol. · Pubmed #19364958 No free full text.

This publication has no abstract.

Uren RF. · No affiliation provided · Ann Surg Oncol. · Pubmed #19363583 No free full text.

This publication has no abstract.

Stretch JR, Scolyer RA. · No affiliation provided · Ann Surg Oncol. · Pubmed #19322612 No free full text.

This publication has no abstract.

Spillane AJ, Winstanley J, Thompson JF. · No affiliation provided · Cancer. · Pubmed #19306419 No free full text.

This publication has no abstract.